Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in
treating young patients with relapsed or refractory solid tumors or leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)